Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma (MREO) EBITDA Margin (2023 - 2025)

Mereo BioPharma (MREO) has disclosed EBITDA Margin for 2 consecutive years, with 1593.8% as the latest value for Q2 2025.

  • Quarterly EBITDA Margin changed N/A to 1593.8% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 10578.75% through Dec 2025, changed N/A year-over-year, with the annual reading at 6770.4% for FY2025, N/A changed from the prior year.
  • EBITDA Margin for Q2 2025 was 1593.8% at Mereo BioPharma, down from 5182.22% in the prior quarter.
  • The five-year high for EBITDA Margin was 5182.22% in Q1 2025, with the low at 1593.8% in Q2 2025.